FR3034019B1 - Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent - Google Patents

Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent

Info

Publication number
FR3034019B1
FR3034019B1 FR1552563A FR1552563A FR3034019B1 FR 3034019 B1 FR3034019 B1 FR 3034019B1 FR 1552563 A FR1552563 A FR 1552563A FR 1552563 A FR1552563 A FR 1552563A FR 3034019 B1 FR3034019 B1 FR 3034019B1
Authority
FR
France
Prior art keywords
oxazino
benzotriazine
antidepressant
dione
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1552563A
Other languages
English (en)
Other versions
FR3034019A1 (fr
Inventor
Sylvie Bretin
Laurence Danober
Pierre Lestage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Priority to FR1552563A priority Critical patent/FR3034019B1/fr
Priority to MA041817A priority patent/MA41817A/fr
Priority to KR1020177024876A priority patent/KR20170125835A/ko
Priority to SG11201706076QA priority patent/SG11201706076QA/en
Priority to EP16718421.7A priority patent/EP3273996A1/fr
Priority to TNP/2017/000280A priority patent/TN2017000280A1/fr
Priority to JP2017549402A priority patent/JP2018509436A/ja
Priority to PCT/FR2016/050681 priority patent/WO2016151265A1/fr
Priority to AU2016238625A priority patent/AU2016238625A1/en
Priority to CA2975571A priority patent/CA2975571A1/fr
Publication of FR3034019A1 publication Critical patent/FR3034019A1/fr
Application granted granted Critical
Publication of FR3034019B1 publication Critical patent/FR3034019B1/fr
Priority to PH12017501248A priority patent/PH12017501248A1/en
Priority to ZA2017/05052A priority patent/ZA201705052B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR1552563A 2015-03-26 2015-03-26 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent Active FR3034019B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR1552563A FR3034019B1 (fr) 2015-03-26 2015-03-26 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
MA041817A MA41817A (fr) 2015-03-26 2016-03-24 NOUVELLE ASSOCIATION ENTRE LE 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g][1,2,3]BENZOTRIAZINE-4,9-DIONE ET UN ANTIDEPRESSEUR ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT
CA2975571A CA2975571A1 (fr) 2015-03-26 2016-03-25 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
EP16718421.7A EP3273996A1 (fr) 2015-03-26 2016-03-25 NOUVELLE ASSOCIATION ENTRE LE 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g][1,2,3]BENZOTRIAZINE-4,9-DIONE ET UN ANTIDEPRESSEUR ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT
TNP/2017/000280A TN2017000280A1 (fr) 2015-03-26 2016-03-25 NOUVELLE ASSOCIATION ENTRE LE 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g] [1,2,3]BENZOTRIAZINE-4,9-DIONE ET UN ANTIDEPRESSEUR ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT
JP2017549402A JP2018509436A (ja) 2015-03-26 2016-03-25 ８−シクロプロピル−３−［２−（３−フルオロフェニル）エチル］−７，８−ジヒドロ−３ｈ−［１，３］オキサジノ［６，５−ｇ］［１，２，３］ベンゾトリアジン−４，９−ジオンと抗うつ剤との新規な組み合わせ、及びそれを含有する医薬組成物
KR1020177024876A KR20170125835A (ko) 2015-03-26 2016-03-25 8-사이클로프로필-3-[2-(3-플루오로페닐)에틸]-7,8-디하이드로-3H-[1,3]옥사지노[6,5-g][1,2,3]벤조트리아진-4,9-디온과 항우울제의 신규한 회합물, 및 이를 함유하는 약제 조성물
AU2016238625A AU2016238625A1 (en) 2015-03-26 2016-03-25 Novel combination of 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3H-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione with an antidepressant, and the pharmaceutical compositions containing same
SG11201706076QA SG11201706076QA (en) 2015-03-26 2016-03-25 Novel combination of 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione with an antidepressant, and the pharmaceutical compositions containing same
PCT/FR2016/050681 WO2016151265A1 (fr) 2015-03-26 2016-03-25 NOUVELLE ASSOCIATION ENTRE LE 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g] [1,2,3]BENZOTRIAZINE-4,9-DIONE ET UN ANTIDEPRESSEUR ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT
PH12017501248A PH12017501248A1 (en) 2015-03-26 2017-07-06 New association between 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione and an antidepresant and pharmaceutical compositions containing it
ZA2017/05052A ZA201705052B (en) 2015-03-26 2017-07-25 Novel combination of 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione with an antidepressant, and the pharmaceutical compositions containing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1552563A FR3034019B1 (fr) 2015-03-26 2015-03-26 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent

Publications (2)

Publication Number Publication Date
FR3034019A1 FR3034019A1 (fr) 2016-09-30
FR3034019B1 true FR3034019B1 (fr) 2017-03-17

Family

ID=53776719

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1552563A Active FR3034019B1 (fr) 2015-03-26 2015-03-26 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent

Country Status (12)

Country Link
EP (1) EP3273996A1 (fr)
JP (1) JP2018509436A (fr)
KR (1) KR20170125835A (fr)
AU (1) AU2016238625A1 (fr)
CA (1) CA2975571A1 (fr)
FR (1) FR3034019B1 (fr)
MA (1) MA41817A (fr)
PH (1) PH12017501248A1 (fr)
SG (1) SG11201706076QA (fr)
TN (1) TN2017000280A1 (fr)
WO (1) WO2016151265A1 (fr)
ZA (1) ZA201705052B (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173644B2 (en) * 2007-01-03 2012-05-08 Les Laboratoires Servier 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
MA41817A (fr) 2018-01-30
SG11201706076QA (en) 2017-08-30
EP3273996A1 (fr) 2018-01-31
FR3034019A1 (fr) 2016-09-30
TN2017000280A1 (fr) 2019-01-16
JP2018509436A (ja) 2018-04-05
ZA201705052B (en) 2019-02-27
CA2975571A1 (fr) 2016-09-29
PH12017501248A1 (en) 2017-10-30
KR20170125835A (ko) 2017-11-15
WO2016151265A1 (fr) 2016-09-29
AU2016238625A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
PL3453707T3 (pl) Pochodna benzazepiny, sposób wytwarzania, kompozycja farmaceutyczna i jej zastosowanie
ZA201900470B (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
EP4324519A3 (fr) Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
GB201913962D0 (en) Ophthalmic drug compositions
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
PT3580208T (pt) Derivados de 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol e compostos relacionados como inibidores de prs para tratamento de, por exemplo, cancro
GB201807968D0 (en) Eutectic extract formation and purification
PL3452075T3 (pl) Oftalmiczna kompozycja farmaceutyczna
IL272638A (en) History of quinoxaline, their preparation and pharmaceutical preparations containing them
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
ZA201908006B (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
PT3606511T (pt) Composição farmacêutica compreendendo mesilato de lenvatinib
WO2017074798A3 (fr) Co-agonistes à action longue durée des récepteurs du glucagon et du glp-1
IL268515A (en) Evolocumab formulations with high concentration and low viscosity and methods for their preparation
IL266132B (en) Pharmaceutical formulations and methods for their preparation
IL283450A (en) capsule formulations
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
EP3476864A4 (fr) Anticorps dirigé contre etar, composition pharmaceutique et utilisation associées
IL266859A (en) Solid oral composition containing dyes
SG11202010792TA (en) Improved pharmaceutical formulations
EP3441075A4 (fr) Composition d'huile essentielle administrée par voie orale et son utilisation
FR3034019B1 (fr) Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
IL271513A (en) Innovative pharmaceutical composition
FR3019464B1 (fr) Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Search report ready

Effective date: 20160930

PLFP Fee payment

Year of fee payment: 3